RecruitingNot ApplicableNCT04144972

Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain

Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain Using Summit RC+S

Sponsor

University of California, San Francisco

Enrollment

12 participants

Start Date

Oct 24, 2019

Study Type

INTERVENTIONAL

Conditions

Post-herpetic neuralgia Pain, Postoperative Nerve Injury Spinal Cord Injuries Complex Regional Pain Syndromes Post Stroke Pain Post Radiation Brain Injury Post Radiation Plexopathy Nerve Root Avulsion

Summary

Chronic pain affects 1 in 4 US adults, and many cases are resistant to almost any treatment. Deep brain stimulation (DBS) holds promise as a new option for patients suffering from treatment-resistant chronic pain, but traditional approaches target only brain regions involved in one aspect of the pain experience and provide continuous 24/7 brain stimulation which may lose effect over time. By developing new technology that targets multiple, complimentary brain regions in an adaptive fashion, the investigators will test a new therapy for chronic pain that has potential for better, more enduring analgesia.

Eligibility

Min Age: 22 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Medtronic Summit RC+S or Percept RC for people with complex regional pain syndromes, nerve injury, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 22 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEMedtronic Summit RC+S or Percept RC

The investigators will perform DBS versus sham (randomized) to evaluate efficacy of stimulation for analgesia. Closed-loop DBS will be compared to open-loop DBS in a patient blinded, randomized fashion after initial, efficacy evaluation.